Combination therapy patents: a new front in evergreening
Nat Biotechnol
.
2021 Dec;39(12):1504-1510.
doi: 10.1038/s41587-021-01137-6.
Authors
Garth W Strohbehn
#
1
2
3
,
Alec J Kacew
1
,
Daniel A Goldstein
2
4
5
6
,
Robin C Feldman
#
7
,
Mark J Ratain
8
9
Affiliations
1
Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA.
2
Optimal Cancer Care Alliance, Ann Arbor, MI, USA.
3
Veterans Affairs Center for Clinical Management and Research, Ann Arbor, MI, USA.
4
Tel Aviv University, Tel Aviv, Israel.
5
Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel.
6
Department of Health Policy and Management, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC, USA.
7
Center for Innovation, University of California Hastings College of the Law, San Francisco, CA, USA.
[email protected]
.
8
Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA.
[email protected]
.
9
Optimal Cancer Care Alliance, Ann Arbor, MI, USA.
[email protected]
.
#
Contributed equally.
PMID:
34880460
DOI:
10.1038/s41587-021-01137-6
No abstract available
MeSH terms
Drug Industry*